報名表及MAbs演講摘要
演講摘要：
There are many monoclonal antibodies (MAbs) in development as therapeutics. Generally, MAbs require a higher dosage (say, 100-1000 mg/dose) than typical protein therapeutics. It is commonly accepted that subcutaneous injections over 1 mL cause skin distortion and pain. As a result, most biotech companies spend much effort concentrating MAbs to 100 mg/mL or more and then trying to stabilize these formulations to avoid aggregates and particulates. Halozyme’s Enhanze™ Technology permits subcutaneous (SC) dosing of much greater than 1 mL per injection, which enables bypassing the formulation challenges associated with achieving high concentrations. A bolus SC injection of 10 mL will be demonstrated. Enhanze technology has the potential to improve the likelihood of formulation success and enable conversion of intravenous (IV) drugs to SC administration, which may benefit patients’ convenience and compliance. Two examples of products using Enhanze technology, SC Herceptin (Roche) and SC GAMMAGARD (Baxter), are in pivotal phase 3 clinical trials. Challenges and opportunities of delivering MAbs through subcutaneous route will be discussed in this presentation.
報名表
姓名：
學校/服務單位：
系所：
聯絡電話(手機)：
E-mail address：
請於6/2前E-mail: cwhsu@mail.ntust.edu.tw或傳真(02)2737-6644 許芷維小姐報名。
